Ondansetron

"Ondansetron" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Descriptor ID	D017294
MeSH Number(s)	D03.383.129.308.690 D03.633.100.473.144.500 D03.633.300.148.500
Concept/Terms	Ondansetron Ondansetron Ondansetron, (+,-)-Isomer Ondansetron, (R)-Isomer Ondansetron, (R)-Isomer Ondansetron, (S)-Isomer Ondansetron, (S)-Isomer GR38032F GR38032F GR-38032F GR 38032F Zofran Zofran Ondansetron Hydrochloride Ondansetron Hydrochloride Hydrochloride, Ondansetron Ondansetron Monohydrochloride Monohydrochloride, Ondansetron Ondansetron Monohydrochloride Dihydrate Dihydrate, Ondansetron Monohydrochloride Monohydrochloride Dihydrate, Ondansetron SN-307 SN-307 SN 307 SN307

Below are MeSH descriptors whose meaning is more general than "Ondansetron".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Ondansetron [D03.383.129.308.690]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Indoles [D03.633.100.473]
Carbazoles [D03.633.100.473.144]
Ondansetron [D03.633.100.473.144.500]
Heterocyclic Compounds, 3-Ring [D03.633.300]
Carbazoles [D03.633.300.148]
Ondansetron [D03.633.300.148.500]

Below are MeSH descriptors whose meaning is more specific than "Ondansetron".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ondansetron" by people in this website by year, and whether "Ondansetron" was a major or minor topic of these publications.

Bar chart showing 15 publications over 10 distinct years, with a maximum of 3 publications in 1996 and 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	3	0	3
2003	1	0	1
2007	1	0	1
2010	2	1	3
2014	1	0	1
2015	0	1	1
2016	0	2	2
2020	0	1	1
2022	0	1	1
2025	1	0	1

Below are the most recent publications written about "Ondansetron" by people in Profiles.

Lam K, Mondick JT, Peltz G, Wu M, Kraft WK. Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome. Clin Transl Sci. 2025 Feb; 18(2):e70147.

View in: PubMed
Peltz G, Jansson LM, Adeniyi-Jones S, Cohane C, Drover D, Shafer S, Wang M, Wu M, Govindaswami B, Jegatheesan P, Argani C, Khan S, Kraft WK. Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. J Perinatol. 2023 03; 43(3):271-276.

View in: PubMed
Spaniolas K, Nie L, Moller D, Tatarian T, Hesketh A, Yang J, Docimo S, Bates A, Gan TJ, Pryor A. A Comprehensive Approach for the Prevention of Nausea and Vomiting Following Sleeve Gastrectomy: a Randomized Controlled Trial. Obes Surg. 2020 11; 30(11):4250-4257.

View in: PubMed
Singh PM, Borle A, Gouda D, Makkar JK, Arora MK, Trikha A, Sinha A, Goudra B. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis. J Clin Anesth. 2016 Nov; 34:459-82.

View in: PubMed
Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database Syst Rev. 2016 May 11; (5):CD010607.

View in: PubMed
Merli GJ, Weitz HH. Web Exclusives. The consult guys - twisted after surgery: what caused torsades? Ann Intern Med. 2015 02 17; 162(4):CG1.

View in: PubMed
Sinha AC, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014 Feb; 24(2):225-31.

View in: PubMed
DiIorio TM, Sharkey PF, Hewitt AM, Parvizi J. Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce nausea and vomiting? Clin Orthop Relat Res. 2010 Sep; 468(9):2405-9.

View in: PubMed
Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1313-21.

View in: PubMed
Mraovic B, Simurina T. Matching groups for studying postoperative nausea and vomiting: should we care? Surg Endosc. 2010 Jul; 24(7):1796-7; author reply 1798-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement